Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;75(9):1330–1335. doi: 10.1038/bjc.1997.225

Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells.

J Budworth 1, T W Gant 1, A Gescher 1
PMCID: PMC2228231  PMID: 9155054

Abstract

The aim of this study was to investigate the link between protein kinase C (PKC) and multidrug resistance (mdr) phenotype. The expression of both was studied in doxorubicin-resistant MCF-7/Adr cells as they reverted to the wild-type phenotype when cultured in the absence of drug. The following parameters were measured in cells 4, 10, 15, 20 and 24 weeks after removal of doxorubicin; (1) sensitivity of the cells towards doxorubicin; (2) levels of P-glycoprotein (P-gp) and MDR1 mRNA; (3) levels and cellular localization of PKC isoenzyme proteins alpha, theta and epsilon; and (4) gene copy number of PKC-alpha and MDR1 genes. Cells lost their resistance gradually with time, so that by week 24 they had almost completely regained the drug sensitivity seen in wild-type MCF-7 cells. P-gp levels measured by Western blot mirrored the change in doxorubicin sensitivity. By week 20, P-gp had decreased to 18% of P-gp protein levels at the outset, and P-gp was not detectable at week 24. Similarly, MDR1 mRNA levels had disappeared by week 24. MCF-7/Adr cells expressed more PKCs-alpha and -theta than wild-type cells and possessed a different cellular localization of PKC-epsilon. The expression and distribution pattern of these PKCs did not change for up to 20 weeks, but reverted back to that seen in wild-type cells by week 24. MDR1 gene amplification remained unchanged until week 20, but then was lost precipitously between weeks 20 and 24. The PKC-alpha gene was not amplified in MCF-7/Adr cells. The results suggest that MCF-7/Adr cells lose MDR1 gene expression and PKC activity in a co-ordinate fashion, consistent with the existence of a mechanistic link between MDR1 and certain PKC isoenzymes.

Full text

PDF
1330

Images in this article

1331Figure 2
on p.1331
1332Figure 3
on p.1332
1333Figure 5
on p.1333

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aftab D. T., Yang J. M., Hait W. N. Functional role of phosphorylation of the multidrug transporter (P-glycoprotein) by protein kinase C in multidrug-resistant MCF-7 cells. Oncol Res. 1994;6(2):59–70. [PubMed] [Google Scholar]
  2. Ahmad S., Glazer R. I. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 1993 Jun;43(6):858–862. [PubMed] [Google Scholar]
  3. Baier G., Baier-Bitterlich G., Meller N., Coggeshall K. M., Giampa L., Telford D., Isakov N., Altman A. Expression and biochemical characterization of human protein kinase C-theta. Eur J Biochem. 1994 Oct 1;225(1):195–203. doi: 10.1111/j.1432-1033.1994.00195.x. [DOI] [PubMed] [Google Scholar]
  4. Bates S. E., Currier S. J., Alvarez M., Fojo A. T. Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochemistry. 1992 Jul 21;31(28):6366–6372. doi: 10.1021/bi00143a002. [DOI] [PubMed] [Google Scholar]
  5. Bates S. E., Lee J. S., Dickstein B., Spolyar M., Fojo A. T. Differential modulation of P-glycoprotein transport by protein kinase inhibition. Biochemistry. 1993 Sep 7;32(35):9156–9164. doi: 10.1021/bi00086a022. [DOI] [PubMed] [Google Scholar]
  6. Beck J., Handgretinger R., Klingebiel T., Dopfer R., Schaich M., Ehninger G., Niethammer D., Gekeler V. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML. Leukemia. 1996 Mar;10(3):426–433. [PubMed] [Google Scholar]
  7. Blobe G. C., Sachs C. W., Khan W. A., Fabbro D., Stabel S., Wetsel W. C., Obeid L. M., Fine R. L., Hannun Y. A. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC alpha. J Biol Chem. 1993 Jan 5;268(1):658–664. [PubMed] [Google Scholar]
  8. Budworth J., Davies R., Malkhandi J., Gant T. W., Ferry D. R., Gescher A. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells. Br J Cancer. 1996 May;73(9):1063–1068. doi: 10.1038/bjc.1996.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chambers T. C., Germann U. A., Gottesman M. M., Pastan I., Kuo J. F., Ambudkar S. V. Bacterial expression of the linker region of human MDR1 P-glycoprotein and mutational analysis of phosphorylation sites. Biochemistry. 1995 Oct 31;34(43):14156–14162. doi: 10.1021/bi00043a021. [DOI] [PubMed] [Google Scholar]
  10. Chambers T. C., McAvoy E. M., Jacobs J. W., Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem. 1990 May 5;265(13):7679–7686. [PubMed] [Google Scholar]
  11. Chambers T. C., Pohl J., Glass D. B., Kuo J. F. Phosphorylation by protein kinase C and cyclic AMP-dependent protein kinase of synthetic peptides derived from the linker region of human P-glycoprotein. Biochem J. 1994 Apr 1;299(Pt 1):309–315. doi: 10.1042/bj2990309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chambers T. C., Pohl J., Raynor R. L., Kuo J. F. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J Biol Chem. 1993 Mar 5;268(7):4592–4595. [PubMed] [Google Scholar]
  13. Chaudhary P. M., Roninson I. B. Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists. Oncol Res. 1992;4(7):281–290. [PubMed] [Google Scholar]
  14. Dahllöf B., Martinsson T., Levan G. Resistance to actinomycin D and to vincristine induced in a SEWA mouse tumor cell line with concomitant appearance of double minutes and a low molecular weight protein. Exp Cell Res. 1984 Jun;152(2):415–426. doi: 10.1016/0014-4827(84)90642-6. [DOI] [PubMed] [Google Scholar]
  15. Davies R., Budworth J., Riley J., Snowden R., Gescher A., Gant T. W. Regulation of P-glycoprotein 1 and 2 gene expression and protein activity in two MCF-7/Dox cell line subclones. Br J Cancer. 1996 Feb;73(3):307–315. doi: 10.1038/bjc.1996.54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dong Z. Y., Ward N. E., Fan D., Gupta K. P., O'Brian C. A. In vitro model for intrinsic drug resistance: effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol Pharmacol. 1991 Apr;39(4):563–569. [PubMed] [Google Scholar]
  17. Fairchild C. R., Ivy S. P., Kao-Shan C. S., Whang-Peng J., Rosen N., Israel M. A., Melera P. W., Cowan K. H., Goldsmith M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987 Oct 1;47(19):5141–5148. [PubMed] [Google Scholar]
  18. Fine R. L., Patel J., Chabner B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci U S A. 1988 Jan;85(2):582–586. doi: 10.1073/pnas.85.2.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Finkenzeller G., Marmé D., Hug H. Sequence of human protein kinase C alpha. Nucleic Acids Res. 1990 Apr 25;18(8):2183–2183. doi: 10.1093/nar/18.8.2183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Fojo A., Lebo R., Shimizu N., Chin J. E., Roninson I. B., Merlino G. T., Gottesman M. M., Pastan I. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet. 1986 Jul;12(4):415–420. doi: 10.1007/BF01570737. [DOI] [PubMed] [Google Scholar]
  21. Gekeler V., Boer R., Uberall F., Ise W., Schubert C., Utz I., Hofmann J., Sanders K. H., Schächtele C., Klemm K. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer. 1996 Sep;74(6):897–905. doi: 10.1038/bjc.1996.454. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Germann U. A., Chambers T. C., Ambudkar S. V., Licht T., Cardarelli C. O., Pastan I., Gottesman M. M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem. 1996 Jan 19;271(3):1708–1716. doi: 10.1074/jbc.271.3.1708. [DOI] [PubMed] [Google Scholar]
  23. Goodfellow H. R., Sardini A., Ruetz S., Callaghan R., Gros P., McNaughton P. A., Higgins C. F. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem. 1996 Jun 7;271(23):13668–13674. doi: 10.1074/jbc.271.23.13668. [DOI] [PubMed] [Google Scholar]
  24. Gupta K. P., Ward N. E., Gravitt K. R., Bergman P. J., O'Brian C. A. Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide. J Biol Chem. 1996 Jan 26;271(4):2102–2111. doi: 10.1074/jbc.271.4.2102. [DOI] [PubMed] [Google Scholar]
  25. Hamada H., Hagiwara K., Nakajima T., Tsuruo T. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 1987 Jun 1;47(11):2860–2865. [PubMed] [Google Scholar]
  26. Madden M. J., Morrow C. S., Nakagawa M., Goldsmith M. E., Fairchild C. R., Cowan K. H. Identification of 5' and 3' sequences involved in the regulation of transcription of the human mdr1 gene in vivo. J Biol Chem. 1993 Apr 15;268(11):8290–8297. [PubMed] [Google Scholar]
  27. Meyers M. B., Spengler B. A., Chang T. D., Melera P. W., Biedler J. L. Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells. J Cell Biol. 1985 Feb;100(2):588–597. doi: 10.1083/jcb.100.2.588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. O'Brian C. A., Fan D., Ward N. E., Seid C., Fidler I. J. Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett. 1989 Mar 27;246(1-2):78–82. doi: 10.1016/0014-5793(89)80257-1. [DOI] [PubMed] [Google Scholar]
  29. Posada J., Vichi P., Tritton T. R. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res. 1989 Dec 1;49(23):6634–6639. [PubMed] [Google Scholar]
  30. Riordan J. R., Deuchars K., Kartner N., Alon N., Trent J., Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. 1985 Aug 29-Sep 4Nature. 316(6031):817–819. doi: 10.1038/316817a0. [DOI] [PubMed] [Google Scholar]
  31. Sachs C. W., Safa A. R., Harrison S. D., Fine R. L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J Biol Chem. 1995 Nov 3;270(44):26639–26648. doi: 10.1074/jbc.270.44.26639. [DOI] [PubMed] [Google Scholar]
  32. Sato W., Yusa K., Naito M., Tsuruo T. Staurosporine, a potent inhibitor of C-kinase, enhances drug accumulation in multidrug-resistant cells. Biochem Biophys Res Commun. 1990 Dec 31;173(3):1252–1257. doi: 10.1016/s0006-291x(05)80921-0. [DOI] [PubMed] [Google Scholar]
  33. Scala S., Dickstein B., Regis J., Szallasi Z., Blumberg P. M., Bates S. E. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clin Cancer Res. 1995 Dec;1(12):1581–1587. [PubMed] [Google Scholar]
  34. Smith C. D., Zilfou J. T. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem. 1995 Nov 24;270(47):28145–28152. doi: 10.1074/jbc.270.47.28145. [DOI] [PubMed] [Google Scholar]
  35. Stanwell C., Gescher A., Bradshaw T. D., Pettit G. R. The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer. 1994 Feb 15;56(4):585–592. doi: 10.1002/ijc.2910560420. [DOI] [PubMed] [Google Scholar]
  36. Ueda K., Cardarelli C., Gottesman M. M., Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A. 1987 May;84(9):3004–3008. doi: 10.1073/pnas.84.9.3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Utz I., Hofer S., Regenass U., Hilbe W., Thaler J., Grunicke H., Hofmann J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer. 1994 Apr 1;57(1):104–110. doi: 10.1002/ijc.2910570119. [DOI] [PubMed] [Google Scholar]
  38. Yu G., Ahmad S., Aquino A., Fairchild C. R., Trepel J. B., Ohno S., Suzuki K., Tsuruo T., Cowan K. H., Glazer R. I. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 1991 Jun;3(6):181–189. doi: 10.3727/095535491820873263. [DOI] [PubMed] [Google Scholar]
  39. Zhang F., Riley J., Gant T. W. Use of internally controlled reverse transcriptase-polymerase chain reaction for absolute quantitation of individual multidrug resistant gene transcripts in tissue samples. Electrophoresis. 1996 Jan;17(1):255–260. doi: 10.1002/elps.1150170144. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES